Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$156,942.00

Vascularized regenerative biomaterials for medical devices and cell therapy

FY 2017-18

Summary
While islet transplantation is a promising treatment for the 1% of Canadians who live with insulin dependent (type 1)diabetes, the majority of islets (perhaps 60%) in current protocols are lost almost immediately upon transplantation. This isdue to inflammatory responses and the lack of blood vessels near the islet which impairs islet survival and function. We havediscovered a unique material that induces the formation of blood vessels and we propose to use this material (as a coatingor as an degradable gel) to generate a medical device (particularly a cell delivery device) that is more functional than iscurrently attainable with conventional materials. The successful use of implantable medical devices is built on thebiocompatibility of inert biomaterials that generate a fibrotic response which isolates the implant from the patient and ensuresthe device is safe. However, this fibrosis precludes the successful use of other devices such as glucose sensors or cellpouches for cell delivery (especially pancreatic islets for diabetes). In this proposal the focus is on a unique Cell PouchSystem produced by an Ontario company, Sernova which is being developed for pancreatic islet delivery to treat diabetes.The unique vascular regenerating biomaterial, based on MAA (methacrylic acid) is expected to enhance vascularization inand around the pouch and so accelerate the ability of islets to respond to elevated glucose levels in diabetic patients.Furthermore the MAA materials (and particularly the degradable gel) are expected to simplify the clinical use (and efficacy ofthe Cell Pouch because it is expected that the device can be implanted and loaded with islets in one step.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
493837-2016
Name nom
Sefton, Michael
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
156942
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Vascularized regenerative biomaterials for medical devices and cell therapy
Keyword
NSERC
Application summary
While islet transplantation is a promising treatment for the 1% of Canadians who live with insulin dependent (type 1)diabetes, the majority of islets (perhaps 60%) in current protocols are lost almost immediately upon transplantation. This isdue to inflammatory responses and the lack of blood vessels near the islet which impairs islet survival and function. We havediscovered a unique material that induces the formation of blood vessels and we propose to use this material (as a coatingor as an degradable gel) to generate a medical device (particularly a cell delivery device) that is more functional than iscurrently attainable with conventional materials. The successful use of implantable medical devices is built on thebiocompatibility of inert biomaterials that generate a fibrotic response which isolates the implant from the patient and ensuresthe device is safe. However, this fibrosis precludes the successful use of other devices such as glucose sensors or cellpouches for cell delivery (especially pancreatic islets for diabetes). In this proposal the focus is on a unique Cell PouchSystem produced by an Ontario company, Sernova which is being developed for pancreatic islet delivery to treat diabetes.The unique vascular regenerating biomaterial, based on MAA (methacrylic acid) is expected to enhance vascularization inand around the pouch and so accelerate the ability of islets to respond to elevated glucose levels in diabetic patients.Furthermore the MAA materials (and particularly the degradable gel) are expected to simplify the clinical use (and efficacy ofthe Cell Pouch because it is expected that the device can be implanted and loaded with islets in one step.
University of Toronto - $156,942 Grant (2017-18) | Canada Spends